Clinical trials: Bladder
Bladder Cancer Requiring Cystectomy
Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial
This is a multi-institutional, randomized trial evaluating oncologic, perioperative, and functional outcomes following two standard care procedures for radical cystectomy.
- Trial name
- NCT01157676
- Testing
- Open radical cystectomy, Robotic assisted radical cystectomy, DaVinci robot
- Where
- 16 sites in United States
- Volunteers
- 350 people
- Sponsor
- University of Miami
Overactive Bladder
Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.
With this study researchers want to gather information about the consumer use behavior of Oxytrol in a simulated setting in which the medicine is sold directly to a consumer without a prescription from a healthcare professional.
- Trial name
- NCT04534491
- Testing
- Oxybutynin (Oxytrol, BAY839380)
- Where
- United States
- Volunteers
- 855 people
- Sponsor
- Bayer
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
This phase II trial is studying how well giving gemcitabine, paclitaxel, and doxorubicin together with pegfilgrastim works in treating patients with metastatic or unresectable bladder cancer or urinary tract cancer and kidney…
- Conditions
- Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT00478361
- Testing
- Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Neoplasms of Urinary Tract, Bladder Cancer
Investigation of Sugammadex in Outpatient Urological Procedures
The goal of this clinical research study is to determine whether using sugammadex, given with a standard muscle relaxation drug during bladder surgeries, improves anesthesia conditions and recovery time.
- Trial name
- NCT03138967
- Testing
- Rocuronium, Sugammadex, Neostigmine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back.
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma
- Trial name
- NCT00749892
- Testing
- Erlotinib Hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Metastatic Bladder Cancer
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
This is a pilot study of avelumab in patients with non-metastatic, muscle invasive bladder cancer who are eligible for radical cystectomy (RC), but are ineligible for cisplatin based neoadjuvant therapy.
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
- Trial name
- NCT03498196
- Testing
- Avelumab
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baylor College of Medicine
Non-muscle Invasive Bladder Cancer (NMIBC)
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
This study, BC-819-18-204, is a Phase 2, open-label, monotherapy, single-arm, multicenter clinical trial of BC-819 (inodiftagene vixteplasmid) in patients with NMIBC adequately treated with Bacillus Calmette-Guerin (BCG) whose…
- Trial name
- NCT03719300
- Testing
- inodiftagene vixteplasmid
- Where
- 48 sites in United States
- Volunteers
- 32 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Bladder Pain Syndrome
The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female participants with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of…
- Trial name
- NCT01569438
- Testing
- Gefapixant
- Where
- 41 sites in United States
- Volunteers
- 107 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
This study will test how well Regorafenib controls disease progression in urothelial cancer (cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous therapy with chemotherapy.
- Trial name
- NCT02459119
- Testing
- Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Non-muscle Invasive Bladder Cancer (NMIBC)
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
A parallel group, open label, multi-centre, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab in recurrent intermediate risk NMIBC.
- Trial name
- PemBla (NCT03167151)
- Testing
- Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Oxford
Bladder Carcinoma, Recurrent Bladder Carcinoma
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
This randomized phase II trial studies how well erlotinib hydrochloride works in treating patients with bladder cancer undergoing surgery.
- Trial name
- NCT02169284
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Overactive Bladder, Urinary Incontinence
Percutaneous Nerve Evaluation With Fluoroscopy Versus Without
The investigators propose a randomized control trial comparing the rate of implantation of the InterStim device following Percutaneous Nerve Evaluation (PNE) performed with or without fluoroscopic guidance.
- Conditions
- Overactive Bladder, Urinary Incontinence, Fecal Incontinence
- Trial name
- NCT02677753
- Testing
- Fluoroscopy
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Head and Neck Neoplasms, Lung Neoplasms
Imaging Study for FdCyd and THU Cancer Treatment
Background: The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how FdCyd works in the body.
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT01479348
- Testing
- [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Urinary Bladder Cancer, Bladder Cancer
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous…
- Conditions
- Urinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms, Bladder Tumors
- Trial name
- NCT00462488
- Testing
- Vicinium
- Where
- 21 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Sesen Bio, Inc.
Advanced Cancer, Metastatic Cancer
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
The main purpose of this study is to evaluate the safety of the study drug known as LY3076226 in participants with advanced or metastatic cancer.
- Trial name
- NCT02529553
- Testing
- LY3076226
- Where
- 4 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Urge Urinary Incontinence
Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
Urge urinary incontinence, characterized by unpredictable and embarrassing large volume urine leakage, is a major health issue for elderly women, as it is incredibly common and significantly impairs quality of life.
- Trial name
- URGE (NCT01786967)
- Testing
- Fesoterodine Fumarate
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of North Carolina, Chapel Hill
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
This is a Phase 1b/2 multi-center, open-label study to establish the initial safety and to determine a recommended Phase 2 dose of B-701 in combination with pembrolizumab, and to determine safety, tolerability and efficacy of…
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Trial name
- FIERCE-22 (NCT03123055)
- Testing
- B-701, Pembrolizumab
- Where
- 52 sites in United States, Belgium and 15 more
- Volunteers
- 28 people
- Sponsor
- Rainier Therapeutics
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion…
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Trial name
- FIERCE-21 (NCT02401542)
- Testing
- Vofatamab, Docetaxel
- Where
- 65 sites in United States, Czechia and 7 more
- Volunteers
- 71 people
- Sponsor
- Rainier Therapeutics
Overactive Bladder
Local Anesthetic Treatments for Overactive Bladder
The purpose of this study is to determine whether alkalized lidocaine instilled into the bladder is effective in the treatment of overactive bladder (OAB).
- Trial name
- NCT00427648
- Testing
- alkalinized xylocaine
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Frank Tu
Overactive Bladder
Foot/Hand Neuromodulation for Overactive Bladder (OAB)
The purpose of this study is to determine if electrical stimulation of the foot is effective in the treatment of overactive bladder conditions.
- Trial name
- FootStim (NCT01972061)
- Testing
- Foot stimulation
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Christopher J Chermansky, MD